Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Insulin-like growth factor I

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Insulin-like growth factor I. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-000644-25 Sponsor Protocol Number: INSM-110-303 Start Date*: 2004-07-09
    Sponsor Name:Insmed Incorporated
    Full Title: A Phase II/III, Open-Label, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of Insulin-Like Growth Factor I/ Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3), Admini...
    Medical condition: Growth Hormone Insensitivity Syndrome (GHIS) is a genetically disturbance of the biological action of growth hormone (GH). This study is intended to evaluate the ability of rhIGF-I/rhIGFBP-3 to de...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000231-27 Sponsor Protocol Number: NN8640-4263 Start Date*: 2019-04-23
    Sponsor Name:Novo Nordisk A/S
    Full Title: A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Trial now transitioned) DK (Completed) AT (Trial now transitioned) SI (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Ongoing) IE (Completed) EE (Completed) LV (Trial now transitioned) PL (Trial now transitioned) HU (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011534-10 Sponsor Protocol Number: 7798 Start Date*: 2009-06-23
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects on insulin sensitivity and body composition of combination therapy with growth hormone (GH) and insulin-like growth factor-I (IGF-I) in growth hormone deficient adults with impaired glucose...
    Medical condition: To evaluate the effect on glucose sensitivity and body composition of combination therapy with GH and IGF-I in growth hormone deficient adults with impaired glucose tolerance or diabetes. The hypot...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003575-11 Sponsor Protocol Number: VitaminD&TT Start Date*: 2013-03-05
    Sponsor Name:Medizinische Universität Graz, Innere Medizin
    Full Title: A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men
    Medical condition: Male hypogonadism (total testosterone <3ng/ml)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10000193 Male sex hormone abnormalities HLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005341-38 Sponsor Protocol Number: P04720 Start Date*: 2008-06-09
    Sponsor Name:Schering Plough Research Institute
    Full Title: A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing’s Sarcoma That Has Relapsed After Standard Systemic Therapy.
    Medical condition: Relapsed resectable and unresectable Osteosarcoma, Ewing Sarcoma.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) SE (Prematurely Ended) NO (Prematurely Ended) NL (Completed) IT (Completed) CZ (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002613-30 Sponsor Protocol Number: GH-3899 Start Date*: 2016-04-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 12-month, open-labelled, randomised, parallel-group, multi-centre, interventional trial to evaluate the efficacy and safety of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) ther...
    Medical condition: Idiopathic short stature
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10066333 Idiopathic short stature LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004269-16 Sponsor Protocol Number: IGFI-1 Start Date*: 2008-02-28
    Sponsor Name:Queen Mary, University of London
    Full Title: Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation.
    Medical condition: Growth failure in children with Crohn's disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000232-10 Sponsor Protocol Number: NN8640-4245 Start Date*: 2019-05-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no ca...
    Medical condition: Short stature in children born small for gestational age with no catch-up growth by 2 years of age or older
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004868 10041093 Small for gestational age LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Trial now transitioned) NO (Ongoing) IE (Completed) EE (Completed) HU (Trial now transitioned) LV (Trial now transitioned) PL (Completed) ES (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004263-47 Sponsor Protocol Number: EMR200104-011 Start Date*: 2013-03-01
    Sponsor Name:Merck KGaA
    Full Title: Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD) of adult onset
    Medical condition: Adult Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-004989-14 Sponsor Protocol Number: Start Date*: 2007-01-12
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: The Effect of Raloxifene on Serum IGF-I in Patients with Acromegaly on long-term Octeotide Treatment
    Medical condition: acromegaly
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003504-12 Sponsor Protocol Number: GK_nilani_2012 Start Date*: 2012-10-05
    Sponsor Name:Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital
    Full Title: Glucocorticoid-induced inhibition of IGF-I activity: exploration of underlying mechanisms.
    Medical condition: The catabolic effects induced by long-term glucocorticoid treatment.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000013-20 Sponsor Protocol Number: NN8640-4042 Start Date*: 2013-12-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, open-labelled, active-controlled, multinational, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of long-acting growth...
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SI (Completed) BE (Completed) AT (Completed) SE (Completed) ES (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-019374-32 Sponsor Protocol Number: CP-4-003 Start Date*: 2010-07-15
    Sponsor Name:ModigeneTech Ltd.
    Full Title: A Phase II, Dose and Frequency Finding Study of MOD-4023 in Growth Hormone Deficient Adults (GHDA)
    Medical condition: Growth Hormone Deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) SI (Completed) CZ (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003796-32 Sponsor Protocol Number: TV1106-IMM-30021 Start Date*: 2015-08-21
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled efficacy, safety and tolerability study of TV-1106 in growth hormone-deficient adults who are not current users of rhGH treatment
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) IT (Completed) AT (Prematurely Ended) ES (Prematurely Ended) SI (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) RO (Prematurely Ended) SK (Prematurely Ended) HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001046-26 Sponsor Protocol Number: NO21200 Start Date*: 2016-09-30
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents with Advanced Solid Tumors
    Medical condition: Recurrent or refractory malignant solid tumors in children between 2 and 17 year of age
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000531-32 Sponsor Protocol Number: NN8640-4172 Start Date*: 2015-12-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: A randomised, multinational, active-controlled,(open-labelled), dose finding, (double-blinded), parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared...
    Medical condition: Growth hormone deficiency in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) SI (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000500-83 Sponsor Protocol Number: 2-55-52060-002 Start Date*: 2008-07-15
    Sponsor Name:Ipsen Pharma
    Full Title: A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients.
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) IT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-000233-37 Sponsor Protocol Number: IGFIMD Start Date*: 2011-04-05
    Sponsor Name:Stockholm Läns Landsting, Karolinska University Hospital
    Full Title: Insulin-like Growth Factor (IGF-I) induced muscle glucose uptake and interstitial IGF-1 concentrations. Placebo controlled, crossover study of the effect of sc rhIGF-I(Increlex) administration on g...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000874-92 Sponsor Protocol Number: LUM-201-01 Start Date*: 2021-03-22
    Sponsor Name:Lumos Pharma, Inc.
    Full Title: A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficie...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003327-23 Sponsor Protocol Number: IP107-001 Start Date*: 2008-10-29
    Sponsor Name:Endo Pharmaceuticals Solutions Inc
    Full Title: PHASE III, OPEN-LABEL, MULTICENTER INTERNATIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AN OCTREOTIDE IMPLANT VERSUS SANDOSTATIN LAR® DEPOT IN PATIENTS WITH ACROMEGALY
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) DE (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 11:30:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA